These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38305038)

  • 21. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients.
    Wang SE; Sun YD; Zhao SJ; Wei F; Yang G
    Math Biosci Eng; 2019 Sep; 17(1):92-104. PubMed ID: 31731341
    [No Abstract]   [Full Text] [Related]  

  • 22. Association between event-free survival and overall survival in early-stage triple-negative breast cancer.
    Huang M; Fasching PA; Haiderali A; Xue W; Pan W; Karantza V; Yang F; Truscott J; Xin Y; O'Shaughnessy J
    Future Oncol; 2024 Feb; 20(6):335-348. PubMed ID: 37602372
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Schwartz KL; Simon MS; Bylsma LC; Ruterbusch JJ; Beebe-Dimmer JL; Schultz NM; Flanders SC; Barlev A; Fryzek JP; Quek RGW
    Cancer; 2018 May; 124(10):2104-2114. PubMed ID: 29505670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Current status and future perspectives for the treatment of triple-negative breast cancer in Japan].
    Masuda N; Yasojima H; Mizutani M; Yamamura J
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):512-8. PubMed ID: 22504674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.
    Wang RX; Chen S; Huang L; Zhou Y; Shao ZM
    Oncologist; 2019 Jun; 24(6):753-761. PubMed ID: 30126858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic and predictive parameters in breast pathology: a pathologist's primer.
    Allison KH
    Mod Pathol; 2021 Jan; 34(Suppl 1):94-106. PubMed ID: 33154551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Platinum-based chemotherapy for early triple-negative breast cancer.
    Mason SR; Willson ML; Egger SJ; Beith J; Dear RF; Goodwin A
    Cochrane Database Syst Rev; 2023 Sep; 9(9):CD014805. PubMed ID: 37681577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics of male triple negative breast cancer: A population-based study.
    Ghani S; Sochat M; Luo J; Tao Y; Ademuyiwa F
    Breast J; 2020 Sep; 26(9):1748-1755. PubMed ID: 32856383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Descriptive study of triple negative breast cancer in Eastern Algeria.
    Souad H; Zahia F; Abdelhak L; Karima S; Dalila S; Noureddine A
    Pan Afr Med J; 2018; 29():45. PubMed ID: 29875927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Shifting Paradigms in TNBC Treatment: Emerging Alternatives to Capecitabine in the Post-Neoadjuvant Setting.
    Abahssain H; Souadka A; Alem R; Santoni M; Battelli N; Amela E; Lemaire A; Rodriguez J; Errihani H
    Curr Oncol; 2024 Jun; 31(7):3771-3782. PubMed ID: 39057150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment patterns and healthcare resource utilization for triple negative breast cancer in the Brazilian private healthcare system: a database study.
    Carlos Souto Maior Borba MA; de Mendonça Batista P; Falcão Almeida M; do Carmo Rego MA; Brandão Serra F; Barbour Oliveira JC; Nakajima K; Silva Julian G; Amorim G
    Sci Rep; 2023 Sep; 13(1):15785. PubMed ID: 37737435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence, treatment patterns, and prognosis of low estrogen receptor-positive (1% to 10%) breast cancer: a single institution's experience in Korea.
    Park YH; Karantza V; Calhoun SR; Park S; Lee S; Kim JY; Yu JH; Kim SW; Lee JE; Nam SJ; Aktan G; Marsico M
    Breast Cancer Res Treat; 2021 Oct; 189(3):653-663. PubMed ID: 34487293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer.
    Kennedy CR; Gao F; Margenthaler JA
    J Surg Res; 2010 Sep; 163(1):52-7. PubMed ID: 20599225
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
    Das U; Lakshmaiah KC; Govind Babu K; Suresh TM; Lokanatha D; Jacob L; Babu S
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1777-82. PubMed ID: 24894013
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.
    Leon-Ferre RA; Polley MY; Liu H; Gilbert JA; Cafourek V; Hillman DW; Elkhanany A; Akinhanmi M; Lilyquist J; Thomas A; Negron V; Boughey JC; Liu MC; Ingle JN; Kalari KR; Couch FJ; Visscher DW; Goetz MP
    Breast Cancer Res Treat; 2018 Jan; 167(1):89-99. PubMed ID: 28913760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S; O'Shaughnessy J; Untch M; Sikov WM; Rugo HS; McKee MD; Huober J; Golshan M; von Minckwitz G; Maag D; Sullivan D; Wolmark N; McIntyre K; Ponce Lorenzo JJ; Metzger Filho O; Rastogi P; Symmans WF; Liu X; Geyer CE
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy in Early-Stage Triple-Negative Breast Cancer: Where Are We Now and Where Are We Headed?
    Dixon-Douglas J; Loi S
    Curr Treat Options Oncol; 2023 Aug; 24(8):1004-1020. PubMed ID: 37222922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.